Shares of Pfizer surged 10% in early trade on Tuesday to ₹4,917.60 on the NSE after the pharma giant reported an 85% year-on-year (YoY) jump in net profit for the fourth quarter ended March 31, 2025. The company posted a net profit of ₹331 crore for Q4FY25, up from ₹179 crore in the same quarter last year.
The stock saw strong investor interest after the company also declared a total dividend of ₹165 per share for FY25. This includes a final dividend of ₹35 per share (350%), a special dividend of ₹100 per share (1000%) to mark its 75th year in India, and an additional ₹30 per share (300%) as gain on asset transfers.
Revenue from operations for Q4FY25 rose 8% to ₹592 crore compared to ₹546.63 crore a year earlier. On the operational front, EBITDA grew 20% to ₹227 crore, while EBITDA margin expanded to 38.4% from 34.75% in the same period last year.
Pfizer shares are currently trading above their 5, 10, 20, 50, and 100-day moving averages, but still remain below the 150- and 200-day averages. The relative strength index (RSI) stands at 69.5, indicating the stock is approaching overbought territory.
Pfizer is engaged in the manufacturing and marketing of pharmaceutical products and caters to a wide base of healthcare institutions, distributors, and government clients.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
